8 completed, 5 unknown, 5 withdrawn, 4 terminated. 27 Phase 2, 10 Phase 1, 3 Phase 3.
Follow Drug Eruptions: new trials by email Literature Review of Drug Eruptions trials Research Report on Drug Eruptions
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Interest of a Targeted Therapy for the Treatment of a Severe Form of Hypersensitivity to Drug (DRESS Syndrome) Benralizumab 30 MG/ML [Fasenra], Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride - DRESS Syndrome | Phase 2 | Not yet recruiting | University Hospital, Lille | 96 | 2027-01-06 | 2026-05-15 |
| TAR-0520 Gel in Hand and Foot Syndrome TAR-0520 gel - Hand and Foot Syndrome | Phase 2 | Not yet recruiting | Tarian Pharma | 25 | 2026-03-01 | 2026-03-09 |
| New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies. DARATUMUMAB (DARZALEX®) - Toxic Epidermal Necrolysis, Immunotherapy | Phase 1 / Phase 2 | Not yet recruiting | Hospices Civils de Lyon | 9 | 2025-10-29 | 2025-08-07 |
| Autologous Serum Obtained by a Closed-Circuit Collection Device Autologous Serum 20% - GVHD, Meibomian Gland Dysfunction (Disorder) | Phase 2 | Active not recruiting | GIANCARLO FATOBENE | 16 | 2025-06-20 | 2026-10-21 |
| Oral Mecobalamin for TKI-Associated Hand-Foot Syndrome in Advanced Thyroid Cancer Mecobalamin, Urea Ointment - Thyroid Cancer, Hand-foot Syndrome | Phase 2 | Completed | Li Zhihui | 100 | 2025-04-12 | 2026-11-03 |
| LYell SYndrome MEsenchymal Stromal Cells Treatment Adipose derived stromal cells intravenously injected - Epidermal Necrolysis, Lyell Syndrome | Phase 1 / Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 15 | 2024-04-15 | 2025-08-01 |
| Effect of Topical Diclofenac on Clinical Outcome in Breast Cancer Patients Treated With Capecitabine (CARBAMIDE®), (VOLTAREN®) Emulgel 1% - Hand and Foot Syndrome | Phase 2 | Completed | German University in Cairo | 86 | 2022-12-08 | 2024-01-03 |
| Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis. Single Dose, Double Dose - Chronic Conjunctivitis, Stevens-Johnson Syndrome | Phase 1 / Phase 2 | Unknown | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | 20 | 2022-11-11 | 2024-07-08 |
| Severe Bullous Drug Eruption and Filgrastim Filgrastim, Placebo - Rare Diseases, Toxic Epidermal Necrolyses | Phase 2 / Phase 3 | Unknown | Hospices Civils de Lyon | 42 | 2022-05-13 | 2024-05-08 |
| Urea Cream Prevention for Capecitabine Associated Hand Foot Syndrome Urea cream - Hand-Foot Syndrome | Phase 2 / Phase 3 | Unknown | Mahidol University | 214 | 2021-12-20 | 2022-04-27 |
| Hydration Based on Thoitaine, Aloe Vera and Calendula, in the Prevention of Hand-Foot Syndrome in Patients Using Capecitabine Extremecare, Placebo - Hand-foot Syndrome | Phase 2 | Unknown | Instituto Brasileiro de Controle do Cancer | 54 | 2019-08-02 | 2021-04-06 |
| The Effect of Topical Brimonidine Tartrate on Hand-foot Syndrome (HFS) in Cancer Patients Brimonidine Tartrate - Hand-foot Syndrome | Phase 2 | Terminated | Heinrich-Heine University, Duesseldorf | 2 | 2017-07-10 | 2019-01-09 |
| Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis Clobetasol 0.05% ointment, Placebo - Toxic Epidermal Necrolysis | Phase 1 / Phase 2 | Withdrawn | University of California, Davis | 2016-11-01 | 2019-08-09 | |
| Topical Infliximab in Autoimmune Eyes With Keratoprosthesis topical infliximab - Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis (Lyell) Syndrome | Phase 1 / Phase 2 | Withdrawn | James Chodosh, MD, MPH | 2014-11-01 | 2017-04-07 | |
| MARY DUOL REPAIR BALM IN THE PREVENTION OR REDUCING ANTINEOPLASIC AGENTS' SKIN TOXICITY BALM ARM, PLACEBO ARM - Dermatitis, Adverse Drug Reaction | Phase 1 / Phase 2 | Unknown | Basque Health Service | 86 | 2014-02-01 | 2016-08-02 |
| Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis Riboflavin - Chemical Injuries, Unspecified Complication of Corneal Transplant | Phase 1 / Phase 2 | Completed | Joseph B. Ciolino, MD | 1 | 2012-03-01 | 2019-10-21 |
| Effectiveness Allopurinol Topical Agent Prevention Capecitabine-induced Hand-foot Syndrome Allopurinol, Placebo - Hand-foot Syndrome | Phase 2 | Completed | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 60 | 2011-07-01 | 2014-05-23 |
| Safety and Efficacy Placebo Controlled Study of ATH008 Cream in PPES Patients Secondary to Capecitabine ATH008 - Palmar-Plantar Erythrodysesthesia Syndrome | Phase 2 | Completed | Advancell - Advanced In Vitro Cell Technologies, S.A. | 122 | 2011-02-01 | 2014-01-30 |
| Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS) Infliximab - Stevens-Johnson Syndrome, Corneal Blindness | Phase 1 / Phase 2 | Withdrawn | Massachusetts Eye and Ear Infirmary | 2010-12-01 | 2015-11-04 | |
| Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis Palifermin - Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome | Phase 1 / Phase 2 | Terminated | Brett King | 1 | 2010-10-01 | 2016-11-30 |
Showing 20 of 27. Sign in to see all of them.
Hand-Foot Syndrome (13) · Stevens-Johnson Syndrome (12) · Breast Neoplasms (3) · Pemphigoid, Benign Mucous Membrane (2) · Arthritis, Rheumatoid (1) · Autoimmune Diseases (1) · Drug Hypersensitivity (1) · Drug Hypersensitivity Syndrome (1) · Graft vs Host Disease (1) · Hyaline Fibromatosis Syndrome (1) · Lupus Erythematosus, Systemic (1) · Meibomian Gland Dysfunction (1) · Neuralgia, Postherpetic (1) · Ovarian Neoplasms (1)
Chemically-Induced Disorders (27) · Dermatitis (27) · Drug-Related Side Effects and Adverse Reactions (27) · Skin Diseases (27) · Skin and Connective Tissue Diseases (27) · Drug Hypersensitivity (26) · Hypersensitivity (13) · Hypersensitivity, Delayed (13) · Immune System Diseases (13) · Erythema (12) · Erythema Multiforme (12) · Mouth Diseases (12) · Skin Diseases, Vesiculobullous (12) · Stomatitis (12)
Infliximab (3) · Allopurinol (1) · Antiperspirants (1) · Brimonidine Tartrate (1) · Clobetasol (1) · Diclofenac (1) · Fibroblast Growth Factor 7 (1) · Filgrastim (1) · Lamotrigine (1) · Ointments (1) · Riboflavin (1) · Sodium Chloride (1) · Solutions (1) · Tobacco Use Cessation Devices (1) · Urea (1)
Hospices Civils de Lyon (2) · Advancell - Advanced In Vitro Cell Technologies, S.A. (1) · Assistance Publique - Hôpitaux de Paris (1) · Basque Health Service (1) · Brett King (1) · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (1) · GIANCARLO FATOBENE (1) · George Washington University (1) · German University in Cairo (1) · Heinrich-Heine University, Duesseldorf (1) · Instituto Brasileiro de Controle do Cancer (1) · Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz (1) · James Chodosh, MD, MPH (1) · Joseph B. Ciolino, MD (1) · Li Zhihui (1)
United States (10) · France (5) · Spain (4) · Brazil (2) · Germany (2) · Belgium (1) · Canada (1) · China (1) · Egypt (1) · Italy (1) · Thailand (1)
James Chodosh, MD, MPH (2) · Claes H Dohlman, MD, PhD (1) · Dr. A. Awada (1) · Emanual Maverakis, MD (1) · Hope S. Rugo, MD (1) · James Cantrell, MD (1) · Jeffrey F Hines, MD, FACOG (1) · Joseph Ciolino, MD (1) · Mona Harissi-Dagher, MD (1) · Patricia Seaone, MD (1) · Paul R Hutson, PharmD (1) · Perry K. Richardson, M.D. (1) · Peter Arne Gerber, PD Dr. med. (1)
PMID 26297574, PMID 28476287, PMID 31931920, PMID 33429738, PMID 38954633, PMID 39962445, PMID 41779386
2025 (1)